| Literature DB >> 18813340 |
Heather B Jaspan1, Lyen C Huang, Mark F Cotton, Andrew Whitelaw, Landon Myer.
Abstract
BACKGROUND: Serious bacterial infections are a major source of morbidity and mortality in HIV-infected children. The spectrum of disease is wide, and responsible organisms vary according to setting. The use of antibiotic prophylaxis and the emergence of multi-drug resistant bacteria necessitate examination of responsible organisms and their antibiotic susceptibility. METHODOLOGY/PRINCIPALEntities:
Mesh:
Substances:
Year: 2008 PMID: 18813340 PMCID: PMC2533121 DOI: 10.1371/journal.pone.0003260
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Demographics and spectrum of serious bacterial disease in hospitalized children with HIV.
| Characteristic | n (%) |
| Gender | |
| Males | 76 (54) |
| Females | 65 (46) |
| On ART | 55 (39) |
| On TB medication | 39 (28) |
| Mortality | 13 (9) |
| Age at admission (yrs) | 1.2 (0.5–2.34) |
| Median (IQR) | |
| Weight at admission (kg) | 6.7 (4.7–9.6) |
| Median (IQR) | |
| Temp. at admission (°C) | 37.3 (36.5–38.3) |
| Median (IQR) | |
| Birth weight (kg) | 2.8 (2.8–3.0) |
| Mean (95% CI) | |
| Hemoglobin on admission | 9.1 (8.1–10.3) |
| Median (IQR) | |
| Concomitant Diagnoses | |
| TB | 40 (28) |
| TB meningitis | 2 (1) |
| Gastroenteritis | 54 (38) |
| PEM | 16 (11) |
| Fungal sepsis | 4 (2.3) |
| Failure to thrive | 29 (21) |
| Bacterial Infections | 40 (28) |
| Bacterial sepsis | 74 (52) |
| Pneumonia | 95 (67) |
| % Bacteremic pneumonia | 50 |
| Bacterial meningitis | 4 (3) |
| % Bacteremic meningitis | 50 |
| Urinary tract infection | 15 (11) |
| % Bacteremic UTI | 87 |
| Skin or soft tissue, including abscess | 2 (1.5) |
| Osteomyelitis or septic arthritis | 1 (0.7) |
ART–antiretroviral therapy, TB–Tuberculosis, PEM-Protein energy malnutrition, IQR–Interquartile range.
Bacterial isolates from hospitalized HIV-infected children with serious bacterial infections*
| Blood n = 128 (% | Urine n = 21 (% | CSF n = 36 (% | N (%) assumed nosocomial (>48 hours) | |
|
| 21 (16) | 1 (2.8) | 2/22 (9%) | |
|
| 14 (11) | 9/14 (64%) | ||
| Coagulase negative staphylococcus | 4 (3) | 4/4 (100%) | ||
|
| 5 (4) | 5 (24) | 7/10 (70%) | |
|
| 11 (9) | 2 (9.5) | 13/13 (100%) | |
| Hemophilus spps | 8 (7) | 1 (2.8) | 1/9 (11%) | |
|
| 1 (1) | 0 | ||
| Non typhoid salmonella | 9 (7) | 1 (4.8) | 7/10 (70%) | |
|
| 1 (1) | 1 (100%) | ||
|
| 4 (3) | 2 (9.5) | 5/6 (83%) | |
|
| 1 (1) | 1 (100%) | ||
|
| 6 (4) | 4/6 (67%) | ||
|
| 1 (1) | 1 (4.8) | 0 | |
| Acinetobacter | 4 (3) | 3/4 (75%) |
Percent of positive cultures, including fungal and mixed or skin flora
Percent of all cultures sent. Urine cultures were not done if urine dipstick was normal unless suspicion was high.
The proportion of nosocomial infections presented here reflects that from children hospitalized for five days or longer, and not necessarily the proportion of nosocomial infections from hospitalizations of all HIV-infected children.
Coagulase negative staphylococcus only included as a pathogen if isolated from more than one culture or with indwelling invasive lines.
Antibiotic susceptibilities of the most common organisms isolated from blood cultures of children with serious bacterial infections, according to time of isolation.
| % susceptible | ||||||||||||
|
|
|
|
| Non-typhoid salmonella |
| |||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Penicillin/Ampicillin | 79 | 50 | 0 | 0 | 100 | 100 | 0 | 50 | 100 | 17 | NA | 0 |
| Amoxicillin +clavulanate | NT | NT | NT | NT | 100 | 100 | 100 | 50 | 100 | 100 | NA | 20 |
| TMP-SMX | NT | NT | 0 | 0 | 67 | 0 | 0 | 75 | 100 | 17 | NA | 0 |
| Cloxacillin/Methicillin | NT | NT | 0 | 0 | NT | NT | NT | NT | NT | NT | NT | NT |
| 3rd generation Cephalosporin | 93 | 100 | NT | NT | 100 | 100 | 100 | 50 | 100 | 20 | NA | 0 |
| Erythromycin | 86 | 50 | 0 | 0 | NT | NT | NT | NT | NT | NT | NT | NT |
| Gentamicin | NT | NT | 0 | 0 | NT | NT | 100 | 50 | NT | NT | NA | 10 |
| Clindamycin | NT | NT | 67 | 33 | NT | NT | NT | NT | NT | NT | NT | NT |
| Ofloxacin/Ciprofloxacin | NT | NT | 33 | 67 | 100 | 100 | 100 | 75 | 100 | 100 | NA | 40 |
| Amikacin | NT | NT | 100 | 78 | NT | NT | 100 | 100 | NT | NT | NA | 90 |
| Pipericillin/Tazobactam | NT | NT | NT | NT | NT | NT | 100 | 75 | 100 | 100 | NA | 50 |
| Meropenem | NT | NT | NT | NT | NT | NT | 100 | 100 | 100 | 100 | NA | 100 |
| Vancomycin | NT | NT | 100 | 100 | NT | NT | NT | NT | NT | NT | NT | NT |
The remainder were intermediate sensitivity
Five isolates intermediate susceptibility
One unknown
NT–not tested
NA–not applicable
TMP-SMX–Trimethoprim sulfamethoxazole